tert-butyl (S)-2-(((2,4,6-triisopropylphenyl)sulfonyl)carbamoyl)indoline-1-carboxylate | 950196-04-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: tert-butyl (S)-2-(((2,4,6-triisopropylphenyl)sulfonyl)carbamoyl)indoline-1-carboxylate
• CAS: 950196-04-0
• 化学式: C₂₉H₄₀N₂O₅S
• 分子量: 528.713
• InChiKey: IJGUDKXRWCOYDS-VWLOTQADSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.23
• 重原子数：
  37.0
• 可旋转键数：
  6.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  92.78
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  tert-butyl (S)-2-(((2,4,6-triisopropylphenyl)sulfonyl)carbamoyl)indoline-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以0.2 g的产率得到(S)-N-[(2,4,6-triisopropylphenyl)sulfonyl]indoline-2-carboxamide
  参考文献：
  名称：

  Application of novel sulfonamides in enantioselective organocatalyzed cyclopropanation

  摘要：

  Three novel aryl sulfonamides derived from (2S)-indoline-2-carboxylic acid have been obtained and used as organocatalysts. The catalysts incorporate diverse functionality on the phenyl ring, enabling steric, and electronic fine tuning of the catalysts. The catalysts facilitate the reaction between a range of alpha, beta-unsaturated aldehydes and sulfur ylides, thus providing cyclopropane products in enantiomeric excesses of up to 99%. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2007.05.030
• 作为产物：
  描述：

  (S)-吲哚啉-2-羧酸 在 吡啶 、 N,N′-二叔丁基碳二亚胺 、 sodium hydride 、 sodium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 叔丁醇 为溶剂， 反应 24.0h， 生成 tert-butyl (S)-2-(((2,4,6-triisopropylphenyl)sulfonyl)carbamoyl)indoline-1-carboxylate
  参考文献：
  名称：

  Application of novel sulfonamides in enantioselective organocatalyzed cyclopropanation

  摘要：

  Three novel aryl sulfonamides derived from (2S)-indoline-2-carboxylic acid have been obtained and used as organocatalysts. The catalysts incorporate diverse functionality on the phenyl ring, enabling steric, and electronic fine tuning of the catalysts. The catalysts facilitate the reaction between a range of alpha, beta-unsaturated aldehydes and sulfur ylides, thus providing cyclopropane products in enantiomeric excesses of up to 99%. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2007.05.030